IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer

Patients with epidermal growth factor receptor (EGFR) mutation-positive lung cancer show a dramatic response to EGFR-tyrosine kinase inhibitors (TKIs). However, acquired drug resistance eventually develops. This study explored the novel mechanisms related to TKI resistance. To identify the genes associated with TKI resistance, an integrative approach was used to analyze public datasets. Molecular manipulations were performed to investigate the roles of insulin-like growth factor binding protein 7 (IGFBP7) in lung adenocarcinoma. Clinical specimens were collected to validate the impact of IGFBP7 on the efficacy of EGFR TKI treatment. IGFBP7 mRNA expression in cancer cells isolated from malignant pleural effusions after acquired resistance to EGFR-TKI was significantly higher than in cancer cells from treatment-naïve effusions. IGFBP7 expression was markedly increased in cells with long-term TKI-induced resistance compared to in TKI-sensitive parental cells. Reduced IGFBP7 in TKI-resistant cells reversed the resistance to EGFR-TKIs and increased EGFR-TKI-induced apoptosis by up-regulating B-cell lymphoma 2 interacting mediator of cell death (BIM) and activating caspases. Suppression of IGFBP7 attenuated the phosphorylation of insulin-like growth factor 1 receptor (IGF-IR) and downstream protein kinase B (AKT) in TKI-resistant cells. Clinically, higher serum IGFBP7 levels and tumors with positive IGFBP7-immunohistochemical staining were associated with poor TKI-treatment outcomes. IGFBP7 confers resistance to EGFR-TKIs and is a potential therapeutic target for treating EGFR-TKI-resistant cancers.

[1]  A. Gemma,et al.  Ankyrin Repeat Domain 1 Overexpression is Associated with Common Resistance to Afatinib and Osimertinib in EGFR-mutant Lung Cancer , 2018, Scientific Reports.

[2]  P. Bertolazzi,et al.  Characterization of epithelial-mesenchymal transition intermediate/hybrid phenotypes associated to resistance to EGFR inhibitors in non-small cell lung cancer cell lines , 2017, Oncotarget.

[3]  P. Mallick,et al.  JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines , 2017, Molecular Cancer Therapeutics.

[4]  M. Ohba,et al.  Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation , 2017, Molecular Cancer Research.

[5]  M. Ohba,et al.  Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI–Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation , 2016, Molecular Cancer Therapeutics.

[6]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[7]  M. You,et al.  Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells , 2016, Molecular carcinogenesis.

[8]  Jun Wang,et al.  IGFBP7 functions as a potential lymphangiogenesis inducer in non-small cell lung carcinoma. , 2016, Oncology reports.

[9]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[10]  J. Shih,et al.  IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer , 2015, Oncotarget.

[11]  B. Klein,et al.  Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma , 2015, Journal of Hematology & Oncology.

[12]  W. Pao,et al.  Acquired resistance to TKIs in solid tumours: learning from lung cancer , 2014, Nature Reviews Clinical Oncology.

[13]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[14]  A. Ruszkiewicz,et al.  IGFBP7 is associated with poor prognosis in oesophageal adenocarcinoma and is regulated by promoter DNA methylation , 2013, British Journal of Cancer.

[15]  D. Heckmann,et al.  The Disparate Twins: A Comparative Study of CXCR4 and CXCR7 in SDF-1α–Induced Gene Expression, Invasion and Chemosensitivity of Colon Cancer , 2013, Clinical Cancer Research.

[16]  J. Minna,et al.  IGFBP2/FAK Pathway Is Causally Associated with Dasatinib Resistance in Non–Small Cell Lung Cancer Cells , 2013, Molecular Cancer Therapeutics.

[17]  T. Ohira,et al.  Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer , 2013, Cellular Oncology.

[18]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[19]  Jie Yang,et al.  MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib , 2013, Molecular oncology.

[20]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[21]  A. Hui,et al.  Potentially Novel Candidate Biomarkers for Head and Neck Squamous Cell Carcinoma Identified Using an Integrated Cell Line-based Discovery Strategy* , 2012, Molecular & Cellular Proteomics.

[22]  Qi-wen Ben,et al.  Low Expression of IGFBP7 is Associated with Poor Outcome of Pancreatic Ductal Adenocarcinoma , 2012, Annals of Surgical Oncology.

[23]  Guangchuang Yu,et al.  clusterProfiler: an R package for comparing biological themes among gene clusters. , 2012, Omics : a journal of integrative biology.

[24]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[25]  L. Tone,et al.  IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginase , 2012, Leukemia.

[26]  Tonsok Kim,et al.  IGFBP7 downregulation is associated with tumor progression and clinical outcome in hepatocellular carcinoma , 2012, International journal of cancer.

[27]  B. Mahon,et al.  Biomarkers of the insulin-like growth factor pathway predict progression and outcome in lung cancer. , 2011, The Annals of thoracic surgery.

[28]  J. Shih,et al.  Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. , 2011, American journal of respiratory and critical care medicine.

[29]  J. Austin,et al.  International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma , 2011, Journal of Thoracic Oncology.

[30]  Gary D Bader,et al.  Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation , 2010, PloS one.

[31]  Jagdish Chandra Patra,et al.  Integration of multiple data sources to prioritize candidate genes using discounted rating system , 2010, BMC Bioinformatics.

[32]  M. Kris,et al.  Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Abbruzzese,et al.  F1000 highlights , 2009, JAMA.

[34]  L. Paz-Ares,et al.  Screening for epidermal growth factor receptor mutations in lung cancer. , 2009, The New England journal of medicine.

[35]  Y. Durocher,et al.  Glioblastoma-secreted factors induce IGFBP7 and angiogenesis by modulating Smad-2-dependent TGF-β signaling , 2008, Oncogene.

[36]  D. Yee,et al.  Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. , 2008, The Journal of clinical investigation.

[37]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[38]  Michael R. Green,et al.  Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7 , 2008, Cell.

[39]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[40]  J. Crowley,et al.  The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[41]  L. Nicholson,et al.  Epigenetic Inactivation Implies Independent Functions for Insulin-like Growth Factor Binding Protein (IGFBP)-Related Protein 1 and the Related IGFBPL1 in Inhibiting Breast Cancer Phenotypes , 2007, Clinical Cancer Research.

[42]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[43]  M. Pacyna‐Gengelbach,et al.  Insulin‐like growth factor binding protein‐related protein 1 (IGFBP‐rP1) has potential tumour‐suppressive activity in human lung cancer , 2007, The Journal of pathology.

[44]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[45]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[46]  A. Seth,et al.  Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors , 2001, Oncogene.

[47]  H. Frierson,et al.  Human prostate cancer expresses the low affinity insulin-like growth factor binding protein IGFBP-rP1. , 1999, Cancer Research.

[48]  Hua Li,et al.  Down-regulation of T1A12/mac25, a novel insulin-like growth factor binding protein related gene, is associated with disease progression in breast carcinomas , 1998, Oncogene.

[49]  Z. Gucev,et al.  Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. , 1996, The international journal of biochemistry & cell biology.

[50]  M. Corkins,et al.  Growth stimulation by transfection of intestinal epithelial cells with an antisense insulin-like growth factor binding protein-2 construct. , 1995, Biochemical and biophysical research communications.

[51]  D. Clemmons,et al.  Insulin-like growth factors and their binding proteins: biological actions. , 1995, Endocrine reviews.

[52]  D. Barnes,et al.  Immunohistochemical detection of p53 protein in mammary carcinoma: an important new independent indicator of prognosis? , 1993, Human pathology.

[53]  R. McCusker,et al.  Secretion of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 by intestinal epithelial (IEC-6) cells: implications for autocrine growth regulation. , 1992, Endocrinology.

[54]  L. Tanoue.  Somatic mutations affect key pathways in lung adenocarcinoma , 2010 .